Sight Sciences

Yahoo Finance • 6 days ago

Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales

Earnings Call Insights: Sight Sciences (SGHT) Q1 2026 MANAGEMENT VIEW * "We delivered a strong start to 2026 with first quarter results that demonstrated a return to double-digit revenue growth, continued strength in gross margin and d... Full story

Yahoo Finance • last month

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to... Full story

Yahoo Finance • last month

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologi... Full story

Yahoo Finance • last month

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Sight Sciences, Inc. Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOB... Full story

Yahoo Finance • 2 months ago

Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whethe... Full story

Yahoo Finance • 2 months ago

Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy

Earnings Call Insights: Sight Sciences (SGHT) Q4 2025 MANAGEMENT VIEW * CEO Paul Badawi stated that the company “ended 2025 with solid execution across our business, highlighted by fourth quarter revenue growth in both segments, strong... Full story

Yahoo Finance • 2 months ago

Sight Sciences (SGHT) Q4 2025 Earnings Transcript

Image source: The Motley Fool. DATE Wednesday, March 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Paul BadawiChief Financial Officer — Jim RodbergChief Operating Officer — Alison Bauerlein Need a quote from a Mo... Full story

Yahoo Finance • 2 months ago

Sight Sciences GAAP EPS of -$0.08 beats by $0.07, revenue of $20.4M beats by $0.06M

* Sight Sciences press release [https://seekingalpha.com/pr/20424655-sight-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-initiates-full] (SGHT [https://seekingalpha.com/symbol/SGHT]): Q4 GAAP EPS of -$0.08 beat... Full story

Yahoo Finance • 2 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologi... Full story

Yahoo Finance • 3 months ago

From REITs to Retail: Small caps with the longest runs at bullish Quant ratings

[silhouette form of bull on technical financial graph 3d illustration] monsitj As 2026 opens with investors seeking dependable small-cap exposure in an uncertain but gradually improving macro environment, below is a list of the top 10 sma... Full story

Yahoo Finance • 6 months ago

Sight Sciences raises 2025 revenue guidance to $76M-$78M while accelerating TearCare commercialization

Earnings Call Insights: Sight Sciences (SGHT) Q3 2025 MANAGEMENT VIEW * Paul Badawi, Co-Founder, President, CEO & Director, reported, "Our strong third quarter results were driven by excellent performance by our Surgical Glaucoma team,... Full story

Yahoo Finance • 6 months ago

Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 7 months ago

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 8 months ago

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies i... Full story

Yahoo Finance • 8 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies i... Full story

Yahoo Finance • 8 months ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies in... Full story

Yahoo Finance • 9 months ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies int... Full story

Yahoo Finance • 9 months ago

Sight Sciences stock rating upgraded by Lake Street on stabilizing business

Investing.com - Lake Street Capital Markets upgraded Sight Sciences Inc. (NASDAQ:SGHT) from Hold to Buy with a price target of $5.00 on Friday. The stock has shown strong momentum, gaining over 8.5% in the past week and trading at $4.13,... Full story

Yahoo Finance • 9 months ago

Sight Sciences raises 2025 revenue guidance to $72M–$76M amid strong OMNI growth and strategic focus on MIGS leadership

Earnings Call Insights: Sight Sciences (SGHT) Q2 2025 MANAGEMENT VIEW * Paul Badawi, CEO, highlighted "our strong second quarter performance underscores the value of our proven interventional technologies for treating glaucoma and dry... Full story

Yahoo Finance • 9 months ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transfor... Full story